UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1183-10
Program Prior Authorization/Notification
Medication Taltz® (ixekizumab)*
*Taltz is excluded from coverage for the majority of our benefits
P&T Approval Date 5/2016, 3/2017, 2/2018, 2/2019, 9/2019, 7/2020, 7/2021, 7/2022,
7/2023, 11/2024
Effective Date 2/1/2025
1. Background:
Taltz (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of
patients aged 6 years or older with moderate to severe plaque psoriasis who are candidates for
systemic therapy or phototherapy. It is also indicated for the treatment of adult patients with
active psoriatic arthritis, active ankylosing spondylitis or non-radiographic axial
spondyloarthritis with objective signs of inflammation.
2. Coverage Criteriaa:
A. Plaque Psoriasis
1. Initial Authorization
a. Taltz* will be approved based on both of the following criteria:
(1) Diagnosis of moderate to severe plaque psoriasis
-AND-
(2) Patient is not receiving Taltz in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),
Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),
Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Taltz will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Taltz therapy
-AND-
© 2024 UnitedHealthcare Services, Inc.
1
(2) Patient is not receiving Taltz in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),
Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),
Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
B. Psoriatic Arthritis
1. Initial Authorization
a. Taltz* will be approved based on both of the following criteria:
(1) Diagnosis of active psoriatic arthritis
-AND-
(2) Patient is not receiving Taltz in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),
Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Taltz will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Taltz therapy
-AND-
(2) Patient is not receiving Taltz in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),
Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
C. Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis
1. Initial Authorization
© 2024 UnitedHealthcare Services, Inc.
2
a. Taltz* will be approved based on both of the following criteria:
(1) Diagnosis of active ankylosing spondylitis or active non-radiographic axial
spondyloarthritis
-AND-
(2) Patient is not receiving Taltz in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),
Olumiant (baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Taltz* will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Taltz therapy
-AND-
(2) Patient is not receiving Taltz in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),
Olumiant (baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
*Taltz is typically excluded from coverage. Tried/failed criteria may be in place. Please refer to plan
specifics to determine exclusion status.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Medical Necessity, Supply limits and/or Step Therapy may be in place.
4. Reference:
1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Co.; August 2024.
© 2024 UnitedHealthcare Services, Inc.
3
Program Prior Authorization/Notification - Taltz (ixekizumab)
Change Control
5/2016 New program
3/2017 Annual review with no change to criteria. Updated reference.
2/2018 Updated background and added criteria for new indication of psoriatic
arthritis. Updated reference.
2/2019 Annual review with no change to criteria. Updated reference.
9/2019 Updated background and criteria to include new indication for active
ankylosing spondylitis. Added coverage exclusion statement. Updated
reference.
7/2020 Updated background and criteria to include new indication for active
non-radiographic axial spondyloarthritis. Changed reauthorization
duration to 12 months. Updated reference.
7/2021 Annual review with no changes to criteria.
7/2022 Annual review with no changes to criteria. Updated examples to align
with Taltz Medical Necessity, added state mandate disclaimer, moved
location of exclusion statement and updated reference.
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
11/2024 Annual review with no changes to coverage criteria. Updated
reference.
© 2024 UnitedHealthcare Services, Inc.
4